All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results PINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30]
1.01 [0.02 ; 51.30 ] PINETREE (GS-US-540-9012), 2021 1 0% 562 NA not evaluable deathsdetailed results PINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30]
1.01 [0.02 ; 51.30 ] PINETREE (GS-US-540-9012), 2021 1 0% 562 NA not evaluable hospitalization or deathdetailed results PINETREE (GS-US-540-9012), 2021 0.13 [0.03; 0.58]
0.13 [0.03 ; 0.58 ] PINETREE (GS-US-540-9012), 2021 1 0% 562 NA not evaluable hospitalizationdetailed results PINETREE (GS-US-540-9012), 2021 0.28 [0.10; 0.77]
0.28 [0.10 ; 0.77 ] PINETREE (GS-US-540-9012), 2021 1 0% 562 NA not evaluable AE leading to drug discontinuationdetailed results PINETREE (GS-US-540-9012), 2021 0.40 [0.08; 2.09]
0.40 [0.08 ; 2.09 ] PINETREE (GS-US-540-9012), 2021 1 0% 562 NA not evaluable serious adverse eventsdetailed results PINETREE (GS-US-540-9012), 2021 0.25 [0.09; 0.69]
0.25 [0.09 ; 0.69 ] PINETREE (GS-US-540-9012), 2021 1 0% 562 NA not evaluable adverse eventsdetailed results PINETREE (GS-US-540-9012), 2021 0.85 [0.61; 1.19]
0.85 [0.61 ; 1.19 ] PINETREE (GS-US-540-9012), 2021 1 0% 562 NA not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-25 15:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 97
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290